Cipla Limited — Important, 23-07-2025: General Updates

Cipla reported robust FY25 performance with 8% revenue growth and 28% PAT increase, marking its highest-ever revenue and EBITDA. North America segment neared $934 million, Africa contributed 15% of revenues, and the India franchise grew 7%. The company remains net cash positive with approximately $1 billion in cash accruals, supporting an annual capex of around INR 2,200 Cr for the next two years. Strategic R&D focuses on complex generics, respiratory, and obesity (GLP-1 launches expected next year). Cipla also emphasizes sustainability, with 67% of India's energy from renewables and 1/3rd of US production in the US to mitigate trade war impacts.